|View printer-friendly version|
Cidara Therapeutics Commends IDSA for New Candidiasis Clinical Management Guidelines
New Guidelines Recommend Echinocandins as First-Line Treatment for Deadly Fungal Infections in High-Risk Patients
Specifically, the guidelines recommend a shift from fluconazole to echinocandins as first-line treatment for invasive candidiasis and candidemia, a bloodstream infection that in vulnerable patients can lead to further complications and death if not treated quickly and appropriately. IDSA Clinical Practice Guidelines are the recognized standard for clinical practice in the infectious diseases community.
“These new guidelines recognize the potency and superior efficacy of
echinocandins as first-line treatment for patients with candidemia and
invasive candidiasis,” said
As the new IDSA guidelines state, echinocandins – which kill fungus – are more effective than fluconazole – which only prevents fungus from growing. Fungal infections, including those caused by strains of Candida, are cause for significant concern, particularly among hospitalized patients. According to the IDSA guidelines, candidemia is associated with mortality rates of up to 47 percent; Candida bloodstream infections are also associated with increased ICU and hospital stays.
While echinocandins have demonstrated safety and efficacy against fungal infections, there is still an unmet need for new antifungal agents due to rising resistance to existing therapies, including the current standard-of-care azole class, and limitations with first-generation echinocandins which require daily IV dosing. Cidara is developing CD101 IV, a novel long-acting, once-weekly echinocandin for the treatment of serious fungal infections. Last month, Cidara reported that data from the company’s Phase 1 single ascending dose (SAD) clinical trial of CD101 IV demonstrated excellent safety and tolerability across a broad range of doses. The company plans to initiate a Phase 2 candidemia trial in the first half of 2016.
The full IDSA guidelines are available on the IDSA website at: www.idsociety.org.
Cidara is a clinical stage biotechnology company focused on the
discovery, development and commercialization of novel anti-infectives
for the treatment of diseases that are inadequately addressed by current
standard-of-care therapies. Cidara's initial product portfolio comprises
two formulations of the company's novel echinocandin, CD101. CD101 IV is
a long-acting therapy for the treatment and prevention of serious,
invasive fungal infections. CD101 topical is for the treatment of
vulvovaginal candidiasis (VVC) and recurrent VVC (RVVC), a prevalent
mucosal infection. In addition, Cidara has developed a proprietary
immunotherapy platform, Cloudbreak™, designed to create compounds that
direct a patient's immune cells to attack and eliminate pathogens that
cause infectious disease. Cidara is headquartered in
Statements contained in this press release regarding matters that are
not historical facts are "forward-looking statements" within the meaning
of the Private Securities Litigation Reform Act of 1995. Because such
statements are subject to risks and uncertainties, actual results may
differ materially from those expressed or implied by such
forward-looking statements. Such statements include, but are not limited
to, statements regarding the effectiveness, safety, long-acting nature,
anticipated human dosing and other attributes of CD101 IV and its
potential to treat infections, the incidence of fungal infections, and
the effectiveness of and treatment protocols for competitive therapies.
Risks that contribute to the uncertain nature of the forward-looking
statements include: the success and timing of Cidara’s preclinical
studies and clinical trials; regulatory developments in